

## **Title**

Enhanced Epidermal Antigen Specific Immunotherapy trial - 1 (EE-ASI-1): A Phase 1a study of gold nanoparticles administered intradermally by microneedles to deliver immunotherapy with a proinsulin derived peptide in Type 1 diabetes.

## **Acronym**

EE-ASI-1

## **Principal/Lead Investigator**

Prof Colin Dayan

## **Participating Sites**

University Hospital Wales

## **Study Summary**

Type 1 diabetes is caused by the body's own white blood cells damaging the insulin-producing cells in the pancreas. The pancreas is then unable to produce any insulin, a hormone that normally controls the amount of sugar (glucose) in the blood. This results in the blood glucose level becoming too high. The aim is to develop a treatment that can slow or stop this process by switching off the white blood cells causing the damage. This treatment involves a molecule similar to insulin attached to small particles of gold (nanoparticles). The aim of this study is to investigate whether this treatment is safe with no significant side-effects.

## **UKCTG Number**

31941

## **Study Sponsor**

Cardiff University